Placental cell therapy for COVID-19 shows early promise but trial halted
NCT ID NCT04365101
First seen Jun 03, 2026 · Last updated Jun 11, 2026 · Updated 4 times
Summary
This study tested an experimental treatment called CYNK-001, made from natural killer cells derived from placental stem cells, in 7 adults with moderate COVID-19. The goal was to see if these immune cells could safely help fight the virus. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atlantic Health
Morristown, New Jersey, 07960, United States
-
Atlantic Health
Summit, New Jersey, 07901, United States
-
Multicare Health System
Tacoma, Washington, 98405, United States
-
UC Irvine
Irvine, California, 92697, United States
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.